JPM 2022: What FDA crackdown? Novartis oncology chief touts BeiGene PD-1’s global profilenews2022-01-11T16:06:51+00:00January 11th, 2022|Fierce Pharma|
China CDMO group ZhenGe Biotech raises $100M in series C financingnews2022-01-11T14:59:30+00:00January 11th, 2022|Fierce Pharma|
JPM 2022: How Novavax plans to be a COVID-19 vaccine force in 2022news2022-01-11T14:31:10+00:00January 11th, 2022|Fierce Pharma|
Selecta taps Ginkgo to create better capsids for gene therapy delivery news2022-01-11T14:27:13+00:00January 11th, 2022|Fierce Pharma|
Kyowa sells U.S. rights to cancer drug delivery patch to Cumberlandnews2022-01-11T14:22:51+00:00January 11th, 2022|Fierce Pharma|
South Korea’s SK commits $350M to help build global cell and gene therapy CDMOnews2022-01-11T13:45:20+00:00January 11th, 2022|Fierce Pharma|
JPM 2022: Bluebird CEO sees ‘unfinished business’ with Zynteglo in Europe, but scale-up needed firstnews2022-01-11T13:24:45+00:00January 11th, 2022|Fierce Pharma|
JPM22, Day 2: GlaxoSmithKline’s ‘landmark year,’ Novavax’s boosting plans and morenews2022-01-11T13:17:08+00:00January 11th, 2022|Fierce Pharma|
JPM22, Day 2: AbbVie’s surprising aesthetics success; Eli Lilly’s tirzepatide plans and morenews2022-01-11T13:17:08+00:00January 11th, 2022|Fierce Pharma|
Ogilvy Health poaches Hessel from Harrison & Star as its new chief creative officernews2022-01-11T08:29:40+00:00January 11th, 2022|Fierce Pharma|
